Rafael Holdings 10-K: Going-Concern Warning With $22.1M Cash After $29.6M FY2026 Loss
RFL is trading near its 52-week low of $1.12 (6.7% above the low) on light trading volume (0.2× avg).
Summary
Rafael Holdings' fiscal 2026 10-K discloses substantial doubt about its ability to continue as a going concern, with $22.1 million of cash left after a $29.6 million net loss and $30.0 million of operating cash burn, plus an unremediated material weakness in internal controls.
Key Events · Earnings and Guidance · RFL
-
Going-Concern Warning Disclosed
Management concluded substantial doubt exists about the Company's ability to continue as a going concern; existing cash is not expected to fund operations through the next twelve months.
-
Cash Fell to $22.1M on Heavy Burn
Cash and equivalents were $22.1 million at July 31, 2026, down $30.7 million from $52.8 million, as operating activities used $30.0 million versus $18.9 million in fiscal 2025.
-
FY2026 Net Loss of $29.6M
Net loss attributable to Rafael Holdings was $29.6 million ($0.58 per share) versus $30.5 million ($1.04) a year earlier; R&D rose to $24.3 million from $12.8 million, including $13.4 million at Cyclo.
-
Material Weakness Still Unremediated
The Cyclo accrual and clinical-trial accrual control weakness identified after the March 2025 merger had not been remediated as of July 31, 2026, so management concluded internal control over financial reporting and disclosure controls were not effective.
Analysis · RFL · Life Sciences
The annual report makes explicit what the September Phase 3 failure set in motion: management states substantial doubt about the Company's ability to continue as a going concern, with $22.1 million of cash at July 31, 2026 against $30.0 million of cash burned in operations during the year. The NDA filed October 28, 2026 rests on a trial that missed its primary endpoint in the overall population, so FDA could refuse to file it or issue a complete response, and the rare pediatric priority review voucher that would be a major source of value is not assured. Layered on top is an unremediated material weakness in Cyclo's accrual and clinical-trial accrual controls, which means disclosure controls were also deemed ineffective. The company needs to raise capital on terms it does not control while its only near-term value driver sits with the FDA.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RFL was trading at $1.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $62.2M. The 52-week trading range was $1.12 to $3.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.